Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Ann Allergy Asthma Immunol. 2022 Feb 3;128(5):535–543.e6. doi: 10.1016/j.anai.2022.01.030

Figure 4:

Figure 4:

A. Comparison of c-ACT/ACT scores at baseline (V1) to scores with guideline care alone (V1-V2) and to scores with guideline + personalized intervention (V2-V3). No distinct differences were observed between clinical phenotype groups. B. Comparison of Emergency Department (ED) utilization at baseline (V1) and following treatment with guideline + personalized intervention (V2-V3). C. Comparison of FEV1/FVC at baseline (V1), at V2 (guideline care alone), and V3 (guideline + personalized intervention) by degree of airway obstruction (normal, mild and moderate).